Screening for human T cell leukaemia/lymphoma virus among blood donors in Sweden: cost effectiveness analysis.
about
Human T-Cell Lymphotropic Virus Types 1 and 2 Seropositivity among Blood Donors at Mbarara Regional Blood Bank, South Western Uganda.HTLV-I/II associated disease in England and Wales, 1993-7: retrospective review of serology requests.Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseasesPharmaco-economics of blood transfusion safety: review of the available evidence.Seroepidemiology of human T-cell lymphotropic virus type-1 (HTLV1) in Mashhad.Human T cell leukaemia/lymphoma virus infection in pregnant women in the United Kingdom: population study.Seroprevalence and geographical distribution of human T-lymphotropic virus type 1 among volunteer blood donors in endemic areas of IranHTLV infection and its implication in gynaecology and obstetrics.Emerging infectious threats to the blood supply: seroepidemiological studies in iran - a reviewHuman T-lymphotropic virus and transfusion safety: does one size fit all?Human T-cell lymphotropic virus testing of blood donors in Norway: a cost-effect model.Reconsideration of blood donation testing strategy for human T-cell lymphotropic virus in Australia.False-reactive microbiologic screening test results in Swedish blood donors-how big is the problem? A survey among blood centers and deferred donors.Prevalence of human T-lymphotropic virus type 1 and 2 infection in Sweden.Seroprevalence of human T-lymphotropic virus type 1 and 2 in Korean blood donors.Long-term survival in transfusion recipients in Sweden, 1993.Human T-lymphotropic virus lookback in NHS Blood and Transplant (England) reveals the efficacy of leukoreduction.The outcome of donor screening for human T-cell lymphotropic virus infection in The Netherlands.Blood safety strategies for human T-cell lymphotropic virus in Europe.Human T-cell leukaemia/lymphoma virus risk may be enhanced in some selected donor populations.Malignancy: Human T-Cell Lymphotropic Virus Type I and Adult T-Cell Leukaemia/Lymphoma.Comparative evaluation of 14 immunoassays for detection of antibodies to the human T-lymphotropic virus types I and II using panels of sera from Sweden and West Africa.Cost-effectiveness of additional blood screening tests in the Netherlands.Survival after blood transfusion
P2860
Q33458088-B1F4426F-C3D1-4B63-AC93-37E49DEEEBE2Q33852814-0286CE5A-A30B-4270-AD22-1861B1EE1854Q33983161-DC0C33D4-CBF8-4B83-9F81-0AE4D653C12FQ34803014-2FE1E24B-AAA0-471A-A123-27537419A3ADQ36780074-D74AE317-E82D-4FAA-A894-DE5DE114C6C9Q37335623-10831FD3-9790-435E-9123-6671EF0661A3Q37615618-27953FB5-627E-46C5-8A20-069924FEE4B1Q37766786-0FED1C30-25ED-4965-9D77-D1CD97AF8D6FQ38127177-D5F54E9D-F232-42ED-BD0B-384FC113B382Q38590004-82F4DF18-928D-4A24-A469-6C8C65ADC6A8Q39491287-AF37225C-66D2-48C2-84E4-D2508847E5ACQ41928215-2D07810A-6BD3-4656-92B2-C24965D2CCA2Q43034940-A5F4C480-0D43-4E5F-91F6-49FBBBD319BDQ43422896-E96A7819-853A-4564-8E3B-973683DC1646Q44045729-2931005F-57CE-41F2-8FD9-273CDD68D8E6Q44681875-9D875029-04A9-43FF-9E62-2392D39EE190Q45352770-A9F573FB-A2DF-439A-A590-F9863AA6DA6CQ45363593-B9F0D649-4D21-4FD8-8462-D6C1E4C72B28Q45388024-D15C46B5-23AB-4DCA-B9CF-E59976E075D5Q45736518-28917673-781B-47CF-BA2A-A1FE0F8D9434Q45736983-21EA8B28-015E-437F-ACFC-AC96EFEDDA4AQ45746987-F7F24A3E-4D33-4A61-B652-4F28A760C357Q55239244-EC82F5B4-CED7-4BF0-A6C7-09F1CF42D2FEQ57579847-41E883D5-EAEF-480A-B9ED-BDDCBD379F1B
P2860
Screening for human T cell leukaemia/lymphoma virus among blood donors in Sweden: cost effectiveness analysis.
description
1998 nî lūn-bûn
@nan
1998 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Screening for human T cell leu ...... : cost effectiveness analysis.
@ast
Screening for human T cell leu ...... : cost effectiveness analysis.
@en
type
label
Screening for human T cell leu ...... : cost effectiveness analysis.
@ast
Screening for human T cell leu ...... : cost effectiveness analysis.
@en
prefLabel
Screening for human T cell leu ...... : cost effectiveness analysis.
@ast
Screening for human T cell leu ...... : cost effectiveness analysis.
@en
P2093
P2860
P1433
P1476
Screening for human T cell leu ...... : cost effectiveness analysis.
@en
P2093
A Bjorkman
A Shanwell
E Lithander
H B Hansson
K Ramstedt
M Arneborn
S Andersson
P2860
P304
P356
10.1136/BMJ.316.7142.1417
P407
P577
1998-05-01T00:00:00Z